PRELP negatively regulates IL-17A-mediated proliferation and the inflammatory response in psoriasis Authors: Cong-cong He, Ming-xing Lei, Jing-wei Jiang, Tao Zhang, Yu-ping Lai, Rui-qun Qi, Xing-Hua Gao Published: 2026 ABSTRACT Psoriasis is a common immune-mediated skin disease driven largely by interleukin-17A (IL-17A). Although IL-17A plays a key role in disease pathogenesis, the underlying mechanisms remain incompletely understood. Through bioinformatic analysis, we discovered that proline/arginine-rich end leucine-rich repeat protein (PRELP) expression is upregulated in skin lesions from psoriasis patients following treatment with IL-17A inhibitors (secukinumab, ixekizumab, and brodalumab), despite being significantly downregulated in lesional compared to nonlesional skin at baseline. Experimental assays confirmed that IL-17A suppressed PRELP expression in keratinocytes, consistent with its reduced expression in lesional tissues from both murine models and human patients. Functionally, PRELP suppressed keratinocyte proliferation, promoted apoptosis, and attenuated activation of the NF-κB and MAPK pathways, along with downstream proinflammatory cytokine and chemokine production. By downregulating IL6 in keratinocytes, PRELP further attenuated local IL-17A production via IL6 modulation, suggesting a break in the feed-forward loop of psoriatic inflammation. Intradermal administration of AAV-K14-PRELP ameliorated psoriasis-like findings in mice, including erythema, scaling, epidermal hyperplasia, and Th17 cell infiltration. Mechanistically, IL-17A suppressed PRELP transcription by activating STAT3, which directly binds to the PRELP promoter as a transcriptional repressor. Collectively, our findings identify PRELP as a negative regulator of IL-17A signaling in psoriasis, acting through keratinocyte dysregulation and modulation of Th17 cells. Therapeutic strategies aimed at enhancing PRELP expression may represent a novel approach for treating psoriasis and other Th17-driven inflammatory diseases. Introduction Psoriasis affects 0.5–8% of the global population with significant regional variation1,2 and a significant disease burden.3 Among its clinical variants, psoriasis vulgaris is the most common form.4 Histologically, psoriatic lesions exhibit acanthosis, parakeratosis, and dermal immune cell infiltration, which are structural manifestations of underlying keratinocyte hyperproliferation and aberrant differentiation.5 The IL-23/Th17 axis has been identified as a central driver in psoriasis pathogenesis.6–8 IL-17A, primarily produced by Th17 cells, promotes keratinocyte proliferation and further activates neutrophils, dendritic cells, and memory T cells.9 Another type of cell that produces IL-17 is the skin-resident T cell, whose infiltration is associated with the recurrence and exacerbation of psoriasis.10 While IL-17A is the dominant therapeutic target, IL-17F homodimers contribute to keratinocyte activation via shared receptors.11 Other cytokines, including TNF, IL36, IL1 and IFN, also play important roles in psoriasis. In line with these pathogenic observations, biologics targeting TNFa, IL-12/IL-23p40, IL-23p19, IL-17A, and IL-17RA have demonstrated substantial clinical efficacy in managing psoriasis.7,12,13 Currently approved IL-17-targeting biologics, including secukinumab, ixekizumab, and brodalumab, have shown significant therapeutic benefit. However, a subset of patients exhibit suboptimal or incomplete responses. Therefore, a complete understanding of the precise role of IL-17A in psoriasis is essential to refine and optimize therapeutic approaches. Using bioinformatic analyses of transcriptomic datasets from psoriasis patients treated with IL-17A-targeting biologics, we identified a consistent upregulation of proline/arginine-rich end leucine-rich repeat protein (PRELP) in lesional skin following treatment with secukinumab, ixekizumab, and brodalumab, although its expression in lesional skin was significantly lower than that in nonlesional skin at baseline.14 PRELP is a class II small leucine-rich proteoglycan (SLRP) and comprises a core protein with two key functional domains: an N-terminal heparin-binding region that interacts with collagen and heparan sulfate and a leucine-rich repeat (LRR) domain that mediates receptor binding.15 Transcription factors such as SOX916 and AHR17 positively regulate PRELP expression, contributing to processes such as collagen synthesis and osteoblast differentiation. In bladder cancer, histone deacetylase (HDAC) inhibitors have been shown to induce PRELP expression by increasing histone H2B acetylation at lysine 5 (H2BK5ac), thereby relieving promoter repression.18 Functionally, PRELP stabilizes the extracellular matrix (ECM) by promoting collagen fibrillogenesis and anchoring the basement membrane while concurrently regulating the TGFb and Wnt pathways by competing ligand/receptor interactions.19 PRELP is widely expressed across various cell types, such as epithelial cells and fibroblasts, as well as in immune cells such as T cells and monocytes. Constitutively expressed in the skin and other barrier tissues, PRELP plays a key role in maintaining epithelial integrity.20 Despite its established role in ECM homeostasis, PRELP’s function in keratinocyte immunobiology is unknown. Notably, PRELP exhibits context-dependent roles in disease: it functions as a tumor suppressor in various solid tumors by impeding metastasis, but it may promote progression in hematologic malignancies.21–23 This functional duality, along with variable prognostic implications across different cancers, underscores the need for tissue-specific mechanistic studies. In this study, we confirmed the expression and functional relevance of PRELP in keratinocytes in vitro and in vivo. Our findings indicate that PRELP plays an important role in IL-17A-driven psoriasis pathogenesis and that its upregulation may offer therapeutic benefits in this setting. Results Expression of PRELP is decreased in psoriatic keratinocytes Based on our published transcriptomic analysis identifying PRELP, FBLN1, and IGFBP5 as top IL-17A-responsive genes in psoriatic keratinocytes,14 we focused on these candidates. Their expression in psoriatic lesions versus healthy skin following IL-17A inhibitor therapy (secukinumab/ixekizumab/brodalumab) is shown in Fig. 1a–d. In a psoriasis model induced by CARD14 gain-of-function mutations, PRELP expression also decreased 30 days after tamoxifen induction (Supplementary Fig. 1a). Treatment with biologics targeting IL-12/IL-23 (ustekinumab) or TNFa (etanercept), as well as cyclosporine, significantly increased PRELP expression in psoriasis patients. In contrast, neither retinoic acid nor IFN-γ had a significant effect (Supplementary Fig. 1b–f). In psoriasis patients treated with brodalumab and stratified by PASI90 response, PRELP expression was significantly upregulated in responders but remained unchanged in nonresponders, despite comparable baseline levels between the two groups (Supplementary Fig. 1g–i). Single-cell analyses of psoriatic skin from 13 patients and 5 controls confirmed epidermis-specific downregulation of PRELP and IGFBP5, while FBLN1 expression remained unchanged (Fig. 1e, Supplementary Fig. 1j, k). Unsupervised clustering identified four keratinocyte subpopulations based on marker genes: KRT5/14 (basal KC), KRT1/10 (spinous KC), SPINK5 (supraspinous KC) and KRT6A (inflammatory KC) (Fig. 1f). In inflammatory keratinocytes, FBLN1 and IGFBP5 expression showed minimal differences between patients and healthy controls, whereas PRELP was significantly downregulated in the patients (Fig. 1g). Immunohistochemistry (IHC) further demonstrated an epidermal-specific reduction in PRELP protein in lesional skin versus skin from healthy controls. In contrast, no significant differences were observed in FBLN1 or IGFBP5 expression patterns between lesional and healthy control skin, either in the epidermis or dermis (Fig. 1h, i), indicating that PRELP downregulation is specific to epidermal keratinocytes in psoriasis. Consistently, PRELP was specifically downregulated in the epidermis but not the dermis in an IMQ-induced mouse inflammatory model (Fig. 1m, n). To directly test IL-17A’s regulatory effect on PRELP, suggested by their inverse correlation in psoriatic lesions, we stimulated NHEKs and HaCaT cells with IL-17A and observed dose- and time-dependent downregulation of PRELP mRNA. In contrast, FBLN1 and IGFBP5 expression was unaffected by IL-17A (Fig. 1o, p, Supplementary Fig. 1l–o). PRELP protein expression also decreased following IL-17A stimulation (Fig. 1q–t, Supplementary Fig. 1p). Furthermore, an M5 cytokine cocktail (IL-17A, IL-22, oncostatin M, IL1a, and TNFa), a cytokine cocktail mimicking psoriatic inflammation, similarly decreased PRELP expression (Supplementary Fig. 1q). We further evaluated the impact of IL-17A/F heterodimers and IL-17F homodimers on PRELP expression. Stimulation of NHEKs with IL-17A/F or IL-17F/F significantly downregulated PRELP mRNA (Supplementary Fig. 1r, s), indicating broader suppression by IL-17 family cytokines. These results demonstrate that PRELP is specifically downregulated in psoriatic lesions, particularly within keratinocytes, in response to IL-17A. To explore the relevance of PRELP in other IL-17A-associated diseases, we analyzed datasets from Crohn’s disease (CD) and axial spondyloarthropathy (axSpA). PRELP expression was reduced significantly in the ileal mucosa of CD patients compared to healthy controls (Supplementary Fig. 1t). Similarly, PRELP was downregulated in the peripheral blood of axSpA patients (Supplementary Fig. 1u). Negative correlations were observed between PRELP and Th17-associated genes (IL23R, STAT3) in both CD and axSpA cohorts (Supplementary Fig. 1v, w), supporting its conserved role as a negative regulator of IL-17-driven inflammatory diseases.Fig. 1Expression of PRELP in psoriatic tissues and keratinocytes. a FBLN1, IGFBP5 and PRELP expression in lesions and nonlesions of psoriasis patients (n = 14); b–d FBLN1, IGFBP5 and PRELP expression before and after treatment with secukinumab (n = 14) (b) ixekinumab (n = 6) (c) and brodalumab (n = 117) (d) in skin of psoriasis patients; e Expression of FBLN1, IGFBP5 and PRELP in the cluster of KC (keratinocytes) in psoriasis scRNA datasets; f Subcluster of KC in psoriasis scRNA datasets; g Relative expression of FBLN1, IGFBP5 and PRELP in 4 clusters of KC; h–j Expression of FBLN1, IGFBP5 and PRELP in psoriasis (n = 14) and normal human skin tissues (n = 6) by IHC assay. Scale bar, 250 μm. k, l Statistical analysis of (h–j); m, n mRNA expression of PRELP in epidermis and dermis of IMQ-induced inflammatory mouse skin (n = 6); o mRNA expression of PRELP in NHEKs (human epidermal keratinocytes) after treatment with 2.5, 5, 10 ng/ml IL-17A for 2 h; p mRNA expression in NHEKs after treatment with 10 ng/ml IL-17A for 0.5, 1 and 2 h; q Protein expression in NHEKs after treatment with 2.5, 5, 10 ng/ml IL-17A for 8 h; r Protein expression in NHEKs after treatment with 10 ng/ml IL-17A for 2, 4 and 8 h; s, t Fluorescence images and mean fluorescence intensity analysis of PRELP expression in HaCaT cells treated with 10 ng/ml IL-17A for 8 h. Scale bar, 200 μm. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, HL: healthy Expression of PRELP in psoriatic tissues and keratinocytes. a FBLN1, IGFBP5 and PRELP expression in lesions and nonlesions of psoriasis patients (n = 14); b–d FBLN1, IGFBP5 and PRELP expression before and after treatment with secukinumab (n = 14) (b) ixekinumab (n = 6) (c) and brodalumab (n = 117) (d) in skin of psoriasis patients; e Expression of FBLN1, IGFBP5 and PRELP in the cluster of KC (keratinocytes) in psoriasis scRNA datasets; f Subcluster of KC in psoriasis scRNA datasets; g Relative expression of FBLN1, IGFBP5 and PRELP in 4 clusters of KC; h–j Expression of FBLN1, IGFBP5 and PRELP in psoriasis (n = 14) and normal human skin tissues (n = 6) by IHC assay. Scale bar, 250 μm. k, l Statistical analysis of (h–j); m, n mRNA expression of PRELP in epidermis and dermis of IMQ-induced inflammatory mouse skin (n = 6); o mRNA expression of PRELP in NHEKs (human epidermal keratinocytes) after treatment with 2.5, 5, 10 ng/ml IL-17A for 2 h; p mRNA expression in NHEKs after treatment with 10 ng/ml IL-17A for 0.5, 1 and 2 h; q Protein expression in NHEKs after treatment with 2.5, 5, 10 ng/ml IL-17A for 8 h; r Protein expression in NHEKs after treatment with 10 ng/ml IL-17A for 2, 4 and 8 h; s, t Fluorescence images and mean fluorescence intensity analysis of PRELP expression in HaCaT cells treated with 10 ng/ml IL-17A for 8 h. Scale bar, 200 μm. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, HL: healthy PRELP downregulates the proliferation and inflammatory response of keratinocytes stimulated by IL-17A Single-cell RNA sequencing data were used to stratify keratinocytes into PRELP-high and PRELP-low-expression groups for differential gene expression and enrichment analysis. In skin from healthy people, genes upregulated in PRELP-high keratinocytes were enriched significantly in pathways related to ribosomal biogenesis (Fig. 2a). In contrast, in psoriatic lesions, high PRELP expression was most strongly associated with apoptotic processes (Fig. 2b), prompting further experimental validation. Notably, the PRELP-low group exhibited elevated expression of Th17 signature genes (RORC, IL-17A, CCR6, and IL23R) compared to the PRELP-high group (Fig. 2c), suggesting that PRELP negatively regulates Th17-associated inflammation. In vitro, lentivirus-mediated PRELP overexpression in NHEKs and HaCaT cells significantly reduced IL-17A-induced proliferation after 24 and 48 h of stimulation (Fig. 2d, Supplementary Fig. 2a). This antiproliferative effect was confirmed using the EdU assay following 24 h of IL-17A stimulation (Fig. 2e, f). Moreover, PRELP overexpression promoted apoptosis, a critical checkpoint disrupted in psoriatic keratinocyte dysregulation (Fig. 2g, h, Supplementary Fig. 2b, c). PRELP overexpression also suppressed IL-17A-induced expression of the proinflammatory cytokines IL1b, IL6, TNFa, CXCL1, CCL20, CXCL8, CXCL9, CXCL10, and S100A7 (Fig. 2i, Supplementary Fig. 2d). Since NF-κB and MAPK mediate IL-17A-driven inflammatory signaling in psoriasis, we examined the phosphorylation status of key components. IL-17A stimulation enhanced the phosphorylation of P65, JNK, P38, and ERK, whereas PRELP overexpression attenuated these phosphorylation events (Fig. 2j). These results demonstrated that PRELP inhibits IL-17A-induced proliferation and inflammation in keratinocytes by inhibiting activation of the downstream NF-κB and MAPK signaling pathways.Fig. 2PRELP regulates the proliferation, apoptosis, and inflammatory response of keratinocyte cells. a, b KEGG enrichment analysis of differentially expressed genes in keratinocytes of PRELP high cells versus low cells in healthy people (a) and psoriasis patients in scRNA datasets (b); c Th17 signature in PRELP high expression cells versus low expression cells in psoriasis scRNA datasets; d Proliferation of NHEKs 24 and 48 h after treatment with 10 ng/ml IL-17A determined using a CCK8 assay; e, f Proliferation of NHEKs 24 h after treatment with 10 ng/ml IL-17A according to the EdU assay. Scale bar, 250 μm. g, h Apoptosis of NHEKs after treatment with 10 ng/ml IL-17A for 24 h using flow cytometry and analysis. i mRNA expression of IL1b, IL6, TNFa, CXCL1, CCL20, CXCL8, CXCL10, and S100A7 in NHEKs overexpressing PRELP treated with 10 ng/ml IL-17A for 4 h. j Expression of P-65, JNK, P-38, ERK and their phosphorylated proteins in HaCaT cells overexpressing PRELP treated with 10 ng/ml IL-17A for 4 h. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 PRELP regulates the proliferation, apoptosis, and inflammatory response of keratinocyte cells. a, b KEGG enrichment analysis of differentially expressed genes in keratinocytes of PRELP high cells versus low cells in healthy people (a) and psoriasis patients in scRNA datasets (b); c Th17 signature in PRELP high expression cells versus low expression cells in psoriasis scRNA datasets; d Proliferation of NHEKs 24 and 48 h after treatment with 10 ng/ml IL-17A determined using a CCK8 assay; e, f Proliferation of NHEKs 24 h after treatment with 10 ng/ml IL-17A according to the EdU assay. Scale bar, 250 μm. g, h Apoptosis of NHEKs after treatment with 10 ng/ml IL-17A for 24 h using flow cytometry and analysis. i mRNA expression of IL1b, IL6, TNFa, CXCL1, CCL20, CXCL8, CXCL10, and S100A7 in NHEKs overexpressing PRELP treated with 10 ng/ml IL-17A for 4 h. j Expression of P-65, JNK, P-38, ERK and their phosphorylated proteins in HaCaT cells overexpressing PRELP treated with 10 ng/ml IL-17A for 4 h. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 STAT3-mediated transcriptional repression of PRELP STAT3 is a key regulator of Th17-associated pathophysiology, coordinating IL-17A-mediated signaling, promoting Th17 cell differentiation, and driving keratinocyte hyperproliferation through autocrine activation. To investigate whether IL-17A suppresses PRELP expression through STAT3, we generated STAT3-silenced NHEKs and HaCaT cells (Fig. 3a, Supplementary Fig. 3a). Upon IL-17A stimulation, STAT3 knockdown resulted in increased PRELP expression at both the mRNA and protein levels (Fig. 3b, c, Supplementary Fig. 3b, c), and an inhibitor of STAT3 also increased the protein expression of PRELP (Supplementary Fig. 3d). Conversely, restoring STAT3 expression in knockdown cells reduced PRELP at both the mRNA and protein levels (Fig. 3d–f), confirming that STAT3 negatively regulates PRELP. To assess whether STAT3 directly represses PRELP transcription, a chromatin immunoprecipitation (ChIP) assay was conducted. STAT3 exhibited an ~3-fold enrichment at the PRELP promoter compared to the IgG control (Fig. 3g, h). Given that NF-κB is another key effector downstream of IL-17A, we investigated its role in regulating PRELP. However, we found that p65 does not bind to the PRELP promoter (data not shown), suggesting that STAT3 mediates a specific regulatory pathway. A dual-luciferase reporter assay further confirmed that STAT3 acts as a negative transcriptional regulator of PRELP. Specifically, STAT3 suppressed luciferase activity from the wild-type PRELP promoter but not from a promoter construct containing mutated STAT3-binding sites (Fig. 3i). These results identify STAT3 as a direct transcriptional repressor of PRELP, mediating its downregulation in response to IL-17A signaling.Fig. 3STAT3 is the transcription factor that negatively regulates the expression of PRELP. a Construction of STAT3 siRNA and verification of its efficiency in NHEKs; b mRNA expression of PRELP in STAT3 interference and 2 h of 10 ng/ml IL-17A treatment NHEKs; c Protein expression of PRELP, STAT3 and P-STAT3 in STAT3 interference and 4 h of 10 ng/ml IL-17A treatment NHEKs; d Construction of STAT3 siRNA and overexpression rescue of its efficiency in HaCaT cells; e mRNA expression of PRELP in STAT3 interference and overexpression rescue in 2 h of 10 ng/ml IL-17A treatment HaCaT cells; f Protein expression of PRELP, STAT3 and P-STAT3 in STAT3 interference and overexpression rescue in 4 h of 10 ng/ml IL-17A treatment HaCaT cells; g, h Binding region of the promoter in PRELP with STAT3 and ChIP assays; i Dual-luciferase reporter assays demonstrating that overexpression of STAT3 significantly inhibited the wild-type PRELP promoter (PRELP-WT) but not the promoter with a mutated STAT3-binding site (PRELP-mut) in 293 T cells were cotransfected with the indicated reporter plasmids and a STAT3 expression plasmid. Relative luciferase activity was calculated by normalizing firefly luciferase activity to Renilla luciferase activity. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 STAT3 is the transcription factor that negatively regulates the expression of PRELP. a Construction of STAT3 siRNA and verification of its efficiency in NHEKs; b mRNA expression of PRELP in STAT3 interference and 2 h of 10 ng/ml IL-17A treatment NHEKs; c Protein expression of PRELP, STAT3 and P-STAT3 in STAT3 interference and 4 h of 10 ng/ml IL-17A treatment NHEKs; d Construction of STAT3 siRNA and overexpression rescue of its efficiency in HaCaT cells; e mRNA expression of PRELP in STAT3 interference and overexpression rescue in 2 h of 10 ng/ml IL-17A treatment HaCaT cells; f Protein expression of PRELP, STAT3 and P-STAT3 in STAT3 interference and overexpression rescue in 4 h of 10 ng/ml IL-17A treatment HaCaT cells; g, h Binding region of the promoter in PRELP with STAT3 and ChIP assays; i Dual-luciferase reporter assays demonstrating that overexpression of STAT3 significantly inhibited the wild-type PRELP promoter (PRELP-WT) but not the promoter with a mutated STAT3-binding site (PRELP-mut) in 293 T cells were cotransfected with the indicated reporter plasmids and a STAT3 expression plasmid. Relative luciferase activity was calculated by normalizing firefly luciferase activity to Renilla luciferase activity. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 Keratinocyte-targeted PRELP delivery ameliorates psoriatic-like lesions in mice Given the ability of PRELP to inhibit IL-17A-induced proliferation and inflammation in keratinocytes, we next investigated its therapeutic potential in vivo. An adeno-associated virus (AAV) driven by a keratin 14 (K14) promoter, specific to keratinocytes, was constructed to overexpress PRELP. It was injected intradermally into mice 14 days before imiquimod application (Fig. 4a). Successful keratinocyte-specific expression of PRELP was confirmed at both the mRNA and protein levels (Fig. 4b–e). AAV-mediated PRELP overexpression significantly alleviated psoriasiform skin inflammation, as evidenced by clinical improvement and reduced epidermal thickness (Fig. 4f–j). Additionally, the expression of the hyperproliferation markers keratin 16 (K16) and proliferating cell nuclear antigen (PCNA) was markedly decreased in PRELP-overexpressing epidermis (Fig. 4k–p). In contrast, the expression of CD31, an endothelial cell marker, remained unchanged (Fig. 4q, r), indicating that vascular remodeling was not affected. Proinflammatory cytokines, including IL1b, IL6, and TNFa, were also reduced significantly in the PRELP-overexpressing group. Notably, MX-1 and ISG15, key markers of the IFN-γ pathway, remained unaltered (Fig. 4s), confirming that PRELP specifically targets IL-17A signaling without affecting interferon responses. To validate the efficacy of PRELP in cytokine-specific psoriasis pathogenesis, we established an IL-23-induced murine model. AAV-K14-PRELP was administered intradermally 14 days before IL-23 injection, achieving robust keratinocyte-specific expression (Supplementary Fig. 4a). PRELP overexpression significantly attenuated IL-23-induced inflammation, with reduced erythema (Supplementary Fig. 4b) and ear thickness (Supplementary Fig. 4c). Histological analyses demonstrated decreased epidermal hyperplasia (Supplementary Fig. 4d, e), paralleling our observations in the IMQ model. Importantly, PRELP suppressed the IL-23-driven cytokine cascade, with significant downregulation of IL-17A, IL-23, TNFa, IL1b, and IL6 mRNA (Supplementary Fig. 4f–j). In contrast, PRELP overexpression did not ameliorate inflammation in a TPA-induced dermatitis model, which is dependent on the IFN-γ pathway. TPA-treated mice showed comparable lesions (Supplementary Fig. 4k), ear thickness changes (Supplementary Fig. 4l), and epidermal hyperplasia (Supplementary Fig. 4m, n) in the AAV-PRELP groups compared to the control groups, underscoring the specificity of PRELPs for IL-17A-driven changes. These results confirm that PRELP effectively intercepts IL-23/Th17 axis signaling at several points.Fig. 4AAV-K14-PRELP applied to the skin alleviates IMQ-induced skin inflammation. a Time axis of the mouse model and skin tissue collected after 7 days of IMQ treatment, n = 5 in the AAV-Vector group, n = 6 in the AAV-PRELP group; b Protein expression of PRELP in mouse skin; c mRNA expression of PRELP in the skin of mice; d, e Immunohistochemistry analysis of PRELP in mouse skin. Scale bar, 250 μm. f Lesions of mice 7 days after IMQ treatment. g–j Clinical scores of mice; k, l H&E staining and analysis of epidermis thickness in mice. Scale bar, 500 μm. m–r Immunohistochemical staining of keratin 16, Scale bar, 500 μm (m), PCNA, Scale bar, 200 μm (o) and CD31, Scale bar, 200 μm (q) and their statistical analysis; s mRNA expression of IL1b, IL6, TNF-a, MX-1, and ISG15 in mouse skin. Data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 AAV-K14-PRELP applied to the skin alleviates IMQ-induced skin inflammation. a Time axis of the mouse model and skin tissue collected after 7 days of IMQ treatment, n = 5 in the AAV-Vector group, n = 6 in the AAV-PRELP group; b Protein expression of PRELP in mouse skin; c mRNA expression of PRELP in the skin of mice; d, e Immunohistochemistry analysis of PRELP in mouse skin. Scale bar, 250 μm. f Lesions of mice 7 days after IMQ treatment. g–j Clinical scores of mice; k, l H&E staining and analysis of epidermis thickness in mice. Scale bar, 500 μm. m–r Immunohistochemical staining of keratin 16, Scale bar, 500 μm (m), PCNA, Scale bar, 200 μm (o) and CD31, Scale bar, 200 μm (q) and their statistical analysis; s mRNA expression of IL1b, IL6, TNF-a, MX-1, and ISG15 in mouse skin. Data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 Keratinocyte-derived PRELP attenuates local IL-17 production via IL-6/IL-23/IL-1 modulation Given the pivotal role of Th17 cells in psoriasis, we next assessed IL-17A production and Th17-related immune responses in PRELP-overexpressing mice. AAV-PRELP administration decreased the expression of IL-17A and IL-23 significantly in psoriatic skin (Fig. 5a, b). Flow cytometric analyses revealed that the proportions and numbers of IL-17A-producing Th17 and γδ T cells were markedly decreased in the skin of K14-PRELP AAV-treated mice compared to controls (Fig. 5c–f). Immunochemistry further confirmed the reduced IL-17A protein expression in the treated group (Fig. 5g-h). In vitro, supernatants from PRELP-overexpressing keratinocytes inhibited the differentiation of naive CD4 + T cells into Th17 cells (Fig. 5i, j). Mechanistically, PRELP decreased IL-17A-induced IL6, IL-23, and IL1b production (Fig. 5k–m), thereby impairing the cytokine-driven differentiation of Th17 cells. To elucidate the mechanism by which PRELP regulates the production of IL6, IL-23, and IL1b, we investigated the NF-κB pathway, a key signaling axis downstream of IL-17A. We found that the addition of TNFa, a potent activator of NF-κB, significantly rescued the suppressive effects of PRELP on these cytokines (Fig. 5n). This indicates that PRELP modulates the expression of key inflammatory cytokines primarily by inhibiting NF-κB signaling.Fig. 5Keratinocyte-derived PRELP attenuates local IL-17A production via IL-6/IL-23/IL-1β modulation. a, b mRNA expression of IL-17A and IL-23 in the skin of mice; c–f Flow cytometry analysis of IL-17A + CD4 + T cells and IL-17A + γδT cells in the skin of mice; g, h Immunohistochemical analysis of IL-17A in the skin of mice. Scale bar, 100 μm. i, j JB6 cells overexpressing PRELP were stimulated with 10 ng/ml IL-17A for 4 h, and then the supernatant was collected and added to naive CD4+ cells together with Th17 differentiation media. The differentiation of TH17 cells was determined by flow cytometry; k–m Secretion of IL6 (k), IL-23 (l), and IL1b (m) by HaCaT cells overexpressing PRELP was stimulated with 10 ng/ml IL-17A for 4 h, as determined by ELISA. n Secretion of IL6, IL-23 and IL1b by HaCaT cells overexpressing PRELP stimulated with 10 ng/ml IL-17A for 4 h as determined by ELISA. TNFa (50 ng/ml) was added 2 h before the addition of IL-17A. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 Keratinocyte-derived PRELP attenuates local IL-17A production via IL-6/IL-23/IL-1β modulation. a, b mRNA expression of IL-17A and IL-23 in the skin of mice; c–f Flow cytometry analysis of IL-17A + CD4 + T cells and IL-17A + γδT cells in the skin of mice; g, h Immunohistochemical analysis of IL-17A in the skin of mice. Scale bar, 100 μm. i, j JB6 cells overexpressing PRELP were stimulated with 10 ng/ml IL-17A for 4 h, and then the supernatant was collected and added to naive CD4+ cells together with Th17 differentiation media. The differentiation of TH17 cells was determined by flow cytometry; k–m Secretion of IL6 (k), IL-23 (l), and IL1b (m) by HaCaT cells overexpressing PRELP was stimulated with 10 ng/ml IL-17A for 4 h, as determined by ELISA. n Secretion of IL6, IL-23 and IL1b by HaCaT cells overexpressing PRELP stimulated with 10 ng/ml IL-17A for 4 h as determined by ELISA. TNFa (50 ng/ml) was added 2 h before the addition of IL-17A. n = 3 for cell experiments, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 PRELP alleviates the features of IMQ-induced skin inflammation in murine skin organoid models To further validate the functional role of PRELP in psoriasis, we employed a murine skin organoid model. Keratinocytes overexpressing PRELP displayed significantly reduced levels of the proliferation marker PCNA compared to controls (Fig. 6a, i). Immunostaining for the keratinocyte-specific markers K14 and E-cadherin revealed a significant decrease in epidermal thickness in the PRELP-overexpressing group (Fig. 6b, c, j, k). In contrast, no significant differences were observed in the expression of the dermal markers tenascin-C (TNC), macrophage coagulation factor XIII A chain (F13A1), or the endothelial marker CD31 (Fig. 6d–f, i–n). Hematoxylin and eosin staining further confirmed reduced epidermal thickness in the PRELP-overexpressing organoids (Fig. 6g, o). Moreover, the levels of IL6, IL-17A, and IL-23 in the skin were decreased significantly in the PRELP-overexpressing group (Fig. 6h, p–r), consistent with our in vivo findings. These results reinforce the conclusion that PRELP attenuates psoriatic inflammation by suppressing keratinocyte hyperproliferation and proinflammatory cytokine production. The reduction in IL6/IL-23 and proliferative markers (PCNA/K14) in PRELP-overexpressing organoids directly aligns with our mechanistic data showing PRELP suppression of the IL6-Th17 axis and NF-kB/MAPK signaling (Fig. 2i, j).Fig. 6PRELP alleviates an IMQ-induced skin inflammation phenotype in mouse skin organoids. a–f, i–n Representative immunofluorescence images of PCNA, K14, Ecad, TNC, F13A1, and CD31 in skin organoids after overexpression of PRELP, statistical analysis of the number of PCNA +, CD31+, and F13A1+ cells, layers of K14+ and Ecad+ cells, and relative fluorescence intensity of TNC. Scale bar, 100 μm. g, o H&E staining and analysis of epidermis thickness in organoids. Scale bar, 50 μm. h, p Representative immunofluorescence images of IL6 and its relative fluorescence intensity. Scale bar, 100 μm. q, r mRNA expression of IL-17A and IL-23 in organoids. s Working model. n = 3, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01 PRELP alleviates an IMQ-induced skin inflammation phenotype in mouse skin organoids. a–f, i–n Representative immunofluorescence images of PCNA, K14, Ecad, TNC, F13A1, and CD31 in skin organoids after overexpression of PRELP, statistical analysis of the number of PCNA +, CD31+, and F13A1+ cells, layers of K14+ and Ecad+ cells, and relative fluorescence intensity of TNC. Scale bar, 100 μm. g, o H&E staining and analysis of epidermis thickness in organoids. Scale bar, 50 μm. h, p Representative immunofluorescence images of IL6 and its relative fluorescence intensity. Scale bar, 100 μm. q, r mRNA expression of IL-17A and IL-23 in organoids. s Working model. n = 3, data are shown as the mean ± SEM, *P < 0.05, **P < 0.01 Discussion Psoriasis is a chronic inflammatory skin disease driven primarily by IL-17A signaling, with genetic studies identifying susceptibility loci across the IL-23-IL-17 axis, including IL-23R, IL-12B, STAT3, and ACT1, which contribute to disease pathogenesis.24,25 Central to the IL-17A response are keratinocytes,26,27 which not only serve as effector cells responding to IL-17A but also actively amplify inflammation by producing cytokines and antimicrobial peptides, which in turn fuel immune cell recruitment and tissue remodeling.28,29 The clinical efficacy of IL-17A-targeting biologics, including ixekizumab,30 secukinumab31, and brodalumab,32 further underscores the centrality of this pathway. These treatments reduce epidermal hyperplasia and dampen immune cell infiltration, largely through mechanisms that suppress keratinocyte proliferation and inflammatory cell signaling. In this study, we identified PRELP as a novel negative regulator of IL-17A-driven psoriatic inflammation. Although previously implicated in extracellular matrix homeostasis33 and tumor suppression,34 our work reveals the previously unrecognized function of IL-17A in cutaneous inflammation. PRELP expression was selectively diminished in psoriatic lesions and further suppressed by IL-17A stimulation, suggesting transcriptional repression as a key cellular event in the disease. Functionally, PRELP inhibited keratinocyte proliferation and promoted apoptosis, effects that align with its tumor-suppressive roles35,36 and directly counteract the pathogenic features of psoriatic epidermal remodeling. Beyond inhibiting proliferation and production of inflammatory factors and psoriasis-associated AMPs (e.g., S100A7), PRELP attenuated keratinocyte-driven immune recruitment via suppression of CXCL1, CXCL8, CXCL10, and CCL20, which are chemokines that recruit neutrophils and T cells.37 This suggests that PRELP in keratinocytes may modulate the crosstalk between keratinocytes and immune cells, thereby playing an important role in the pathogenesis of psoriasis. At the molecular level, our findings suggest that PRELP exerts its anti-inflammatory effects in part by dampening the MAPK and NF-κB pathways, which are central to keratinocyte activation and cytokine production in psoriasis. Moreover, we demonstrate that PRELP’s inhibition of key Th17-polarizing cytokines, including IL6, IL-23, and IL1b, is primarily mediated through its suppression of the NF-κB pathway, as activation of NF-κB signaling rescued their production. These cytokines attenuate the expansion and cytokine production of tissue-resident memory T cells (TRM), the primary IL-17A producers in established psoriatic lesions, which are key players in psoriasis chronicity and recurrence.10,38 This finding positions PRELP as a central modulator of the IL-23/Th17 axis. By disrupting CCL20-CCR6 chemotaxis and IL6/IL-23/IL1b signaling, PRELP limits the infiltration and local expansion of pathogenic IL-17A⁺ T cells. The clinical relevance of PRELP is further underscored by its differential regulation by established psoriasis therapies. Our analyses reveal that effective treatments such as TNFa inhibitors and cyclosporine significantly upregulate PRELP expression in psoriatic lesions, suggesting that the restoration of this endogenous brake may contribute to their therapeutic efficacy. In contrast, retinoid drugs such as etretinate did not affect PRELP levels, highlighting the specificity of PRELP integration into specific inflammatory pathways (e.g., TNFa/NF-κB and IL-17A) rather than universal responsiveness. Equally important is PRELP’s pathway specificity. In the TPA-induced dermatitis model, a well-established IFN-γ/Th1-dominant model is independent of IL-17 signaling.39 AAV-mediated PRELP overexpression failed to ameliorate inflammation. This absence of efficacy underscores that PRELP’s function is intrinsically linked to IL-17A/Th17 biology rather than generic anti-inflammatory activity. From a therapeutic perspective, this selectivity is advantageous: it minimizes off-target effects on protective IFN-γ-mediated immunity (e.g., antiviral defense) and supports PRELP as a target for Th17-driven pathologies. This finding further helps to explain why PRELP restoration did not alter IFN-γ-responsive genes (MX-1, ISG15) in our psoriatic models, reinforcing its niche role in modulating specific cytokine circuits. Additionally, IL-17F homodimers and IL-17A/F heterodimers could also reduce the expression of PRELP. Further study should also focus on the specific function of PRELP in those pathways, given their emerging clinical relevance.40 Notably, our study may extend the relevance of PRELP beyond psoriasis to other IL-17A-driven diseases. We observed significant downregulation of PRELP in the ileal mucosa of CD patients and peripheral blood of axSpA patients, conditions where IL-17A/Th17 dysregulation is a known pathogenic driver.41,42 The negative correlation between PRELP and Th17 markers (IL23R, STAT3) in these diseases suggests a conserved role for PRELP as a universal checkpoint in Th17-mediated inflammation across epithelial and stromal barriers. Therapeutic strategies targeting PRELP could thus have broad applicability, potentially benefiting patients with psoriatic arthritis, inflammatory bowel disease, or spondyloarthropathies that exhibit inadequate responses to current biologic drugs. Mechanistically, we demonstrate that IL-17A-induced suppression of PRELP is mediated through STAT3, a transcription factor with well-established roles in Th17 differentiation and keratinocyte activation. Using ChIP‒qPCR and luciferase reporter assays, we confirmed STAT3 binding to a specific site in the PRELP promoter and showed that this interaction suppresses PRELP transcription. Interestingly, this finding contrasts with the canonical view that STAT3 typically activates transcription and that its repressor function occurs via recruitment of corepressors (e.g., HDACs) to specific genomic loci. Our data align with established models wherein STAT3 recruits HDAC complexes to deacetylate histones,18,43,44 explaining its tissue-specific repressive role. Although the precise identity of STAT-associated corepressors in this context remains to be elucidated, our findings open new avenues for understanding cell type-specific transcriptional repression in inflammation. Collectively, our data position PRELP as a dual-function regulator that directly suppresses keratinocyte-driven inflammation and indirectly modulates T-cell responses. By coordinately suppressing IL6, IL-23, and IL1b through NF-κB inhibition, PRELP delivers a multifaceted blow to the Th17 differentiation pathway (Fig. 6s). Unlike many STAT3-driven genes that amplify inflammation, PRELP is uniquely suppressed by STAT3, creating a self-reinforcing inflammatory cycle: heightened IL-17A/STAT3 signaling silences PRELP, which in turn removes a key brake on the very pathway that suppresses it. PRELP sets a threshold for immune activation, and its downregulation in lesions represents not only a consequence but also a permissive factor for disease chronicity. These findings highlight the potential for developing PRELP-based local therapies, such as recombinant protein or peptide mimetics, as a novel therapeutic avenue for psoriasis. The significant upregulation of PRELP exclusively in treatment responders provides compelling evidence that its restoration is an active component of therapeutic efficacy, not merely an epiphenomenon of inflammation resolution. This identifies patients lacking this PRELP response as a distinct endotype with impaired homeostasis, for whom direct PRELP targeting represents a novel therapeutic avenue. Although our study demonstrates that PRELP functions primarily in keratinocytes to modulate the local inflammatory milieu, we cannot exclude potential effects on immune cells. While PRELP is known to interact with integrins on keratinocytes and fibroblasts,45 its receptor expression on dendritic cells has not been reported. Interestingly, decorin, a related small leucine-rich proteoglycan, modulates dendritic cell activity and suppresses Th17 differentiation.46 Future studies will investigate whether PRELP can similarly regulate dendritic cells and whether such regulation contributes to its antipsoriatic effects. While transgenic models remain valuable for chronic disease modeling, our AAV approach offers precise spatiotemporal control of PRELP expression, closely mimicking clinical delivery strategies for psoriasis. Further investigation is warranted to delineate the full spectrum of PRELP’s regulatory network, including its upstream regulators and downstream transcriptional targets. Understanding the context-dependent roles of STATs in PRELP repression and defining the epigenetic machinery involved will be critical for translating these findings into targeted interventions. Modulating PRELP expression or function may represent a new class of therapeutic strategies that synergize with existing IL-17 pathway inhibitors or offer alternatives in patients with therapeutic resistance. The direct effects of TNFa, IL-23, and IL6, key components of the IL-17A/STAT3 axis, on PRELP expression should be further investigated to elucidate the precise regulatory mechanisms. Materials and methods Microarray data analysis Gene expression datasets were retrieved from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.govgeo/): GSE137218, GSE31652, and GSE117468: Psoriasis patients treated with IL-17A inhibitors (secukinumab, ixekizumab, or brodalumab); GSE11903: Psoriasis patients treated with etanercept; GSE58558: Atopic dermatitis patients treated with cyclosporine; GSE58749: Primary human keratinocytes treated with retinoic acid or 3,4-didehydroretinoic acid; GSE117239: Psoriasis patients treated with ustekinumab; GSE32407: Healthy volunteers and nonlesional psoriasis patients at baseline or 24 h after placebo/IFN-γ injection; GSE149880: Transcriptomic profile of an inducible CARD14 gain-of-function mouse model (knock-in ear tissue). GSE75214: Crohn’s disease (CD) patients versus healthy controls (ileal mucosa); GSE18781: axSpA patients versus healthy controls (peripheral blood). Genes with an adjusted p value < 0.05 were considered significantly differentially expressed. Single-cell RNA sequencing analysis The scRNA-Seq dataset GSE151177, comprising 13 human psoriatic skin lesion samples and 5 healthy control samples, was obtained from the GEO database. Data processing was performed using the Seurat package in R (version 4.1). Quality control steps included filtering out genes expressed in fewer than 10 cells, cells expressing fewer than 200 unique genes, and cells with mitochondrial transcript content exceeding 30%. Batch effects were corrected using Harmony (theta=2, lambda=1). Dimensionality reduction was performed using uniform manifold approximation and projection (UMAP), and cell clusters were annotated based on canonical markers from the CellMarker database.47 Clinical samples and immunohistochemistry Formalin-fixed paraffin-embedded skin tissues were obtained from the tissue bank of The First Hospital of China Medical University, including samples from 19 psoriasis patients and 6 healthy controls. Sections were deparaffinized in xylene and rehydrated through a graded ethanol series. Antigen retrieval was performed in citrate buffer (pH 6.0) at 95 °C for 20 min. After blocking with 5% BSA for 1 h at room temperature, slides were incubated overnight at 4 °C with rabbit anti-human PRELP primary antibody (1:100 dilution; Zenbio, Cat# ZB-2301, China) in a humidified chamber. Detection was carried out using the EliVision Super HRP Kit (Maixin, Cat# KIT-0021, China) with DAB chromogen, followed by hematoxylin counterstaining. All procedures involving human samples were approved by the Ethics Committee of the First Hospital of China Medical University (Approval No.: 2021-255). Cell culture The human keratinocyte cell lines HaCaT (SCSP-5091, SIBCB, China) and JB6 (ml00391, mlbio, China) were cultured in DMEM or MEM supplemented with 10% fetal bovine serum and 1% penicillin‒streptomycin and maintained at 37 °C/5% CO₂ atmosphere. Normal human epidermal keratinocytes (NHEKs) were purchased from SUNNCELL Company (China) and cultured in keratinocyte serum-free medium (KSFM) supplemented with epidermal growth factor (EGF) and bovine pituitary extract (BPE). Cells were maintained at 37 °C in a humidified 5% CO2 atmosphere, with medium changes every 48 h. Transfection with PRELP lentivirus (Genechem, Shanghai, China) was performed at a multiplicity of infection (MOI) of 20. After 72 h of transfection, puromycin selection was applied to enrich stably transfected cells. The control group was transfected with empty vector lentivirus under identical conditions. STAT3-targeting siRNA (Sangon, China) was transfected into cells using Lipofectamine™ RNAiMAX (Thermo Fisher Scientific, USA). DNA plasmids (Genechem, Shanghai, China) were transfected using Lipofectamine 3000 (Thermo Fisher Scientific, USA) according to the manufacturer’s protocol. For each well of a 6-well plate, 2 µg of plasmid DNA was used. The M5 cocktail consisted of IL1a (10 ng/ml), IL-22 (10 ng/ml), TNFa (10 ng/ml), IL-17A (10 ng/ml), and OSM (10 ng/ml), and all cytokines were purchased from Proteintech. STAT3-IN-11 (MCE, China) at 10 µM for 6 h was used to inhibit the activity of STAT3. Mouse inflammatory skin model To induce IMQ-induced skin inflammation, 6–8-week-old C57BL/6 mice (18–20 g) (Changsheng, China) received daily topical applications of 62.5 mg imiquimod (IMQ) cream on shaved dorsal skin for 7 consecutive days; control mice were treated with Vaseline. For the IL-23 model, 500 ng IL-23 in 20 μl (R&D Systems, USA) was injected daily into the dermis of the ear of anesthetized mice on each of 4 consecutive days. For the phorbol 12-myristate 13-acetate (TPA)-induced dermatitis model, TPA (Sigma, USA) was diluted in a 7:1 ratio of acetone to dimethyl sulfoxide (DMSO) and applied daily to the right ear of each mouse at a dose of 2.5 μg/mouse from day 0 to day 6. For in vivo PRELP overexpression, K14 promoter-driven PRELP adeno-associated virus (AAV-K14-PRELP; 1 × 10¹¹ viral genomes, Genechem) was intradermally injected 14 days before drug application, 5–7 sites at the back and 2 sites at the ear (20 µl per site). All animal protocols were approved by the China Medical University Animal Ethics Committee (Approval No.: KT2023252). Mouse skin organoids Skin organoids were generated as previously described.48 Primary cells were extracted from the dorsal skin of neonatal mice (within 24 h of birth). After dissection, connective tissue was carefully removed, and the skin was then digested overnight at 4 °C in 20 mL of 0.25% EDTA-free trypsin (Sigma, #T4549). The epidermis and dermis were separated using fine forceps. Dermis tissue was subsequently digested with collagenase (Worthington, #LS004197) at 37 °C for 30 min, followed by filtration and centrifugation to isolate dermal cells. Epidermal and dermal cells were then cocultured at a 1:9 ratio in DMEM/F12 medium (Corning #10092018) using a 12-well Transwell system. From day 3 to day 7 of culture, inflammatory priming was performed using IL-17A (10–15 μM), IL-23 (10–15 μM), TNFa (5–10 μM), IL1a (5–10 μM), and galectin 9 (2–5 μg/mL). To confirm the successful establishment of our organoids and verify the presence of immune cell populations, we performed single-cell RNA sequencing in previous studies. The results demonstrated that our organoid system contains macrophages, T cells, dendritic cells, and other immune cell subtypes (data not shown). Quantitative PCR (QPCR) Total RNA was extracted using the MiRNeasy Mini Kit (Qiagen, Germany) following the manufacturer’s instructions. RNA quantity and purity were assessed using a NanoDrop ND1000 spectrophotometer. Complementary DNA (cDNA) was synthesized with the GoScript Reverse Transcription Kit (Promega), and qPCR was performed using RT2 SYBR Green qPCR Mastermix (Promega, USA). Each 10 µl qPCR included 1 µl cDNA, 0.2 µl each of forward and reverse primers, 5 µl 2 x qPCR Master Mix, 0.1 µl SYBR dye, and 3.5 µl nuclease-free water. Reactions were run on a 7900HT Fast Real-Time PCR System (Applied Biosystems, USA) with the following cycling conditions: 95 °C for 2 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. A melting curve was included to confirm product specificity. Primer sequences are listed in Supplementary Table S1. Western blotting Cells were lysed in RIPA buffer (Beyotime, China) containing protease and phosphatase inhibitors. Protein lysates (30 μg per lane) were separated by SDS‒PAGE and transferred onto PVDF membranes. Membranes were blocked and incubated with primary antibodies against PRELP (1:1000; Zenbio), phospho-/total-JNK, ERK, p38, and p65 (1:2000; CST). After washing, the membranes were incubated with HRP-conjugated secondary antibodies (1:5000; Jackson), and signals were visualized using ECL chemiluminescence reagent (Tanon, China) and captured with a chemiluminescence imaging system (Tanon, China). Chromatin immunoprecipitation (ChIP) Cells were crosslinked with 1% formaldehyde for 10 min at room temperature, followed by quenching and lysis. Chromatin was sonicated to 200–500 bp fragments and immunoprecipitated with anti-STAT3 (CST #9139) or IgG as a control. DNA‒protein complexes were reverse-crosslinked, and immunoprecipitated DNA was purified and analyzed by qPCR using primers targeting the PRELP promoter region. Dual-LUC reporter gene assay The STAT3 expression plasmid, empty vector, and PLREP WT and PRELP promoter mutant plasmids (Baihaobio, China) were cotransfected into HEK293T cells using Lipo 3000 (Thermo Fisher Scientific, USA). For PRELP promoter mutant plasmids, the −326 to −316 bp region, whose sequence was 5’-CTTGCTGGAAG-3’, was mutated to 5’-CTTGGTGGTGG-3’. Renilla luciferase was used as an internal control. Luciferase activity was measured using the Dual-Luciferase Reporter Assay Kit (Beyotime Biotechnology, Shanghai, China) following the manufacturer’s instructions. Immunofluorescence Cells were fixed with 4% paraformaldehyde (Beyotime, China) for 15 min at room temperature, followed by permeabilization and blocking with 1% BSA and 0.1% Triton X-100 (Beyotime, China) for 10 min. Cells were incubated overnight at 4 °C with primary antibody and then washed and incubated with Alexa Fluor 488-conjugated anti-rabbit secondary antibody (CST, USA) for 1 h at room temperature. Cell nuclei were stained with DAPI for 5 min at room temperature, and fluorescence images were acquired using a fluorescence microscope. CCK8 assay Cell proliferation was assessed using the Cell Counting Kit-8 (Beyotime, China). After treatment, 10 µl of CCK-8 reagent was added to each well and incubated for 2 h at 37 °C. Absorbance was measured at 450 nm using a microplate reader. Apoptosis assay Apoptosis was analyzed using the FITC Annexin V Apoptosis Detection Kit (BD Biosciences, USA). Following treatment, the cells were harvested, washed with PBS, and resuspended in binding buffer. FITC-conjugated Annexin V and PI were added and incubated in the dark at RT for 15 min. Samples were analyzed by flow cytometry to determine the percentage of apoptotic cells. Isolation of naive CD4 + T cells and induction of Th17 cells Naive CD4 + T cells were isolated from the spleens of 8- to 10-week-old female C57BL/6 mice (Changsheng, China). Fresh spleens were mechanically dissociated through a 40-µm sterile nylon filter to obtain single-cell suspensions. Naive CD4 + T cells were enriched using the Mouse Naive CD4 + T Cell Isolation Kit (Miltenyi Biotec, Germany) via negative selection, following the manufacturer’s instructions. Cells were cultured in Th17-polarizing medium composed of 10 μg/ml anti-IL-4 antibodies, 5 μg/ml anti-CD28 antibodies, 10 μg/ml anti-IFN-γ antibodies, 20 ng/ml IL-23, 20 ng/ml IL6, 10 ng/ml TNFa, and 2 ng/ml TGFb. Cells were seeded at 4–5 × 105 cells/ml into 96- or 24-well plates precoated with anti-CD3 antibody. Two days later, the culture media was replaced with supernatant collected from JB6 keratinocyte cultures. Following an additional 2-day incubation, cells and supernatants were collected for downstream analyses, including flow cytometry, western blotting, and ELISA for IL-17A. Flow cytometric analysis Cell viability was assessed using a fixable viability dye (564997, BD Biosciences) for 30 min at 4 °C. Surface markers were stained with anti-mouse CD4 (566407, BD Biosciences) and anti-mouse TCRγδ antibodies (BioLegend, China) for 30 min at 4 °C in the dark. Cells were then fixed and permeabilized using the BD Cytofix/Cytoperm kit (51-2090KZ; BD Biosciences), followed by intracellular staining with anti-mouse IL-17A antibody (BioLegend, China) for 50 min at 4 °C. Data acquisition was performed on a BD LSRFortessa cytometer, and analyses were conducted using FlowJo software. ELISA The concentrations of IL6, IL-23, and IL1b in cell culture supernatants were quantified using commercial sandwich ELISA kits (Cusabio, China) according to the manufacturer’s protocols. Briefly, after blocking with a suitable buffer, samples and standards were added and incubated. Target cytokines were bound by biotinylated detection antibodies, followed by incubation with streptavidin-HRP. The reaction was developed with a TMB substrate and stopped with sulfuric acid, and the absorbance was measured at 450 nm. Cytokine concentrations were determined by interpolation from the standard curve. Statistical analysis All statistical analyses were conducted using GraphPad Prism 7 (GraphPad Software, San Diego, CA). For comparisons between two groups (both in vitro and in vivo), a two-tailed unpaired Student’s t test was used, assuming a normal distribution and homogeneity of variance. For comparisons involving three or more groups, one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was applied after verifying normality and variance homogeneity. Data are presented as the mean ± standard deviation (SD) for technical replicates (e.g., intraexperiment triplicates) and as the mean ± standard error of the mean (SEM) for biological replicates or independent experiment repeats to distinguish measurement precision from biological variability. A P value < 0.05 was considered statistically significant. Supplementary information Supplementary_Materials WB RAW DATA Supplementary_Materials WB RAW DATA